288 related articles for article (PubMed ID: 17356950)
1. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Elias D; Goere D; Blot F; Billard V; Pocard M; Kohneh-Shahri N; Raynard B
Ann Surg Oncol; 2007 Jun; 14(6):1818-24. PubMed ID: 17356950
[TBL] [Abstract][Full Text] [Related]
2. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
[TBL] [Abstract][Full Text] [Related]
3. Peritoneal carcinomatosis of colorectal origin.
Elias D; Raynard B; Farkhondeh F; Goéré D; Rouquie D; Ciuchendea R; Pocard M; Ducreux M
Gastroenterol Clin Biol; 2006 Oct; 30(10):1200-4. PubMed ID: 17075479
[TBL] [Abstract][Full Text] [Related]
4. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
Elias D; Raynard B; Boige V; Laplanche A; Estphan G; Malka D; Pocard M
J Surg Oncol; 2005 Jun; 90(4):220-5. PubMed ID: 15906364
[TBL] [Abstract][Full Text] [Related]
5. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.
Elias D; Matsuhisa T; Sideris L; Liberale G; Drouard-Troalen L; Raynard B; Pocard M; Puizillou JM; Billard V; Bourget P; Ducreux M
Ann Oncol; 2004 Oct; 15(10):1558-65. PubMed ID: 15367418
[TBL] [Abstract][Full Text] [Related]
6. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J
J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
[TBL] [Abstract][Full Text] [Related]
8. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
9. Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis.
Spiliotis J; Rogdakis A; Vaxevanidou A; Datsis A; Zacharis G; Christopoulou A
J BUON; 2009; 14(2):259-64. PubMed ID: 19650176
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.
Glockzin G; Gerken M; Lang SA; Klinkhammer-Schalke M; Piso P; Schlitt HJ
BMC Cancer; 2014 Nov; 14():807. PubMed ID: 25369730
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
[TBL] [Abstract][Full Text] [Related]
12. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients.
Elias D; Sideris L; Pocard M; Edè C; Ben Hassouna D; Ducreux M; Boige V; Côté JF; Lasser P
Ann Oncol; 2004 May; 15(5):781-5. PubMed ID: 15111347
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
Elias D; Benizri E; Di Pietrantonio D; Menegon P; Malka D; Raynard B
Ann Surg Oncol; 2007 Feb; 14(2):509-14. PubMed ID: 17096054
[TBL] [Abstract][Full Text] [Related]
17. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
[TBL] [Abstract][Full Text] [Related]
18. The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Gómez Portilla A; Cendoya I; Olabarría I; Martínez de Lecea C; Gómez Martínez de Lecea C; Gil A; Martín E; Muriel J; Magrach L; Romero E; Lirola A; Guede N; Moraza N; Fernández E; Kvadatze M; Valdovinos M; Larrabide I; Ruiz de Alegría N; Fernández JL; Castillo C; Rua O; Ulibarrena MA
Rev Esp Enferm Dig; 2009 Feb; 101(2):97-102, 103-6. PubMed ID: 19335045
[TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
20. Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
Delhorme JB; Triki E; Romain B; Meyer N; Rohr S; Brigand C
J Visc Surg; 2015 Jun; 152(3):149-54. PubMed ID: 25650364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
